The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bristol Myers Squibb Foundation; EUSA Pharma; Ipsen; Merck Serono; Pfizer
Consulting or Advisory Role - Merck Serono; Pfizer
Research Funding - Ipsen (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen
 
Travel, Accommodations, Expenses - Bayer
Other Relationship - Janssen
SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.
 
Robert J. Jones
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EUSA Pharma; Ipsen; Janssen; Merck Serono; MSD Oncology; Novartis; Pfizer; Pharmacyclics; Roche/Genentech; Sanofi; Seagen
Consulting or Advisory Role - Clovis Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen; MSD
 
Amit Bahl
Honoraria - Bristol-Myers Squibb; Pfizer; Sanofi/Aventis
Research Funding - Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Roche
 
Johann S. De Bono
Employment - Institute of Cancer Research
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
 
Christy Ralph
Honoraria - Eisai
Consulting or Advisory Role - Eisai
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan
 
Tony Elliott
Research Funding - GlaxoSmithKline (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Janssen
 
Angus Robinson
Travel, Accommodations, Expenses - Roche
 
Charlotte Westbury
No Relationships to Disclose
 
Alison Jane Birtle
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer Schering Pharma; Janssen Oncology; Roche; Sanofi
Speakers' Bureau - Bayer; Janssen Oncology; Pfizer
Research Funding - Genzyme
 
John Nicholas Staffurth
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Janssen
Travel, Accommodations, Expenses - AstraZeneca; Janssen
 
Andrew Protheroe
Honoraria - Astellas Oncology; Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Bayer; EUSA Pharma; Merck Sharp & Dohme; Roche
 
Balaji Venugopal
No Relationships to Disclose
 
Fiona Thomson
Stock and Other Ownership Interests - AstraZeneca; MSD
Consulting or Advisory Role - TherapeutAix
Research Funding - AstraZeneca (Inst); BioNTech (Inst); MSD (Inst); Nucana (Inst); Roche (Inst)
 
Chantevy Pou
No Relationships to Disclose
 
Karen Morris
No Relationships to Disclose
 
Jonathan Tugwood
Consulting or Advisory Role - AstraZeneca (I)
 
Laura Divers
No Relationships to Disclose
 
Carol Hopkins
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); Eisai (I); MSD (I); Nucana (I); Pierre Fabre (I)
 
Elaine McCartney
No Relationships to Disclose
 
Caroline Kelly
No Relationships to Disclose
 
Simon J. Crabb
Honoraria - Astellas Pharma; Bayer; MSD; Roche
Consulting or Advisory Role - AstraZeneca; BeiGene; Janssen-Cilag; Pfizer; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Clovis Oncology
Expert Testimony - MSD
Travel, Accommodations, Expenses - Bayer; Janssen-Cilag; MSD; MSD; Roche